A5020431898- Hematopoietic Stem Cell Transplantation
- Urinary Tract Infections Management
- Antibiotics Pharmacokinetics and Efficacy
- Acute Lymphoblastic Leukemia research
- Platelet Disorders and Treatments
- Antibiotic Resistance in Bacteria
- COVID-19 Clinical Research Studies
- COVID-19 epidemiological studies
- COVID-19 and healthcare impacts
- Acute Myeloid Leukemia Research
- Blood groups and transfusion
Saarland University
2022-2025
Platelet reconstitution after allogeneic hematopoietic cell transplantation (allo‐HCT) is heterogeneous and influenced by various patient‐ transplantation‐related factors, associated with poor prognoses for graft function (PGF) isolated thrombocytopenia. Tailored interventions could improve the outcome of patients PGF post‐HCT To provide individual predictions 180‐day platelet counts from early phase data, we developed a model long‐term allo‐HCT. A large cohort ( n = 1949) adult undergoing...
ABSTRACT We investigated the pharmacokinetics (PK) of intravenous fosfomycin in critically ill patients undergoing different types kidney replacement therapy (KRT) to identify optimized dosing regimens for patient care. Four prospective, observational studies contributed data with prolonged-intermittent KRT (PIKRT, n =18), continuous (CKRT, =15), or without ( =12) population PK analysis. Subsequently, licensed daily dosages (12–24 g), varying estimated glomerular filtration rates (eGFR,...
The coronavirus disease 2019 (COVID-19) pandemic challenged many national health care systems, with hospitals reaching capacity limits of intensive units (ICU). Thus, the estimation acute local burden ICUs is critical for appropriate management resources. In this work, we applied non-linear mixed effects modeling to develop an epidemiological SARS-CoV-2 infection model Germany, its 16 federal states and 400 districts, that describes infections as well COVID-19 inpatients, ICU patients...
The aim of this study was to investigate the pharmacokinetics multiple-dose intravenous (i.v.) fosfomycin in critically ill patients during continuous venovenous hemodialysis (CVVHD). Non-compartmental analysis and population pharmacokinetic modeling were used simulate different dosing regimens. We evaluated 15 with renal insufficiency CVVHD undergoing anti-infective treatment our ICU. Five grams administered for 120 min every 6 h. Plasma concentrations determined without CVVHD....
Acute graft-versus-host disease (aGvHD) is a major cause of death for patients following allogeneic hematopoietic stem cell transplantation (HSCT). Effective management moderate to severe aGvHD remains challenging despite recent advances in HSCT, emphasizing the importance prophylaxis and risk factor identification.